Literature DB >> 21182886

Peroxynitrite-induced modification of H2A histone presents epitopes which are strongly bound by human anti-DNA autoantibodies: role of peroxynitrite-modified-H2A in SLE induction and progression.

Kiran Dixit1, M Asad Khan, Y D Sharma, Khursheed Alam.   

Abstract

Peroxynitrite is a potent oxidant and nitrating agent and has in vivo existence. It is a powerful proinflammatory substance and may increase vascular permeability in inflamed tissues. Systemic lupus erythematosus (SLE) is an autoimmune inflammatory disease of unknown etiology. Since its discovery, numerous self- and non-self, nuclear, and cytoplasmic antigens have been suggested as stimuli for SLE initiation, but the exact trigger is yet to be identified. In this study, an attempt has been made to investigate the binding characteristics of SLE anti-DNA autoantibodies to native DNA and native and peroxynitrite-modified H2A histone to explore the possible role of modified protein antigen(s) in SLE initiation and progression. The nuclear protein (H2A histone) was modified by peroxynitrite synthesized in our laboratory. The peroxynitrite-modified H2A revealed generation of nitrotyrosine, dityrosine, and carbonyls when subjected to investigation by physicochemical methods. Binding characteristics and specificity of SLE anti-DNA antibodies were analyzed by direct binding and inhibition enzyme-linked immunosorbent assay. The data show preferential binding of SLE autoantibodies to peroxynitrite-modified H2A histone in comparison with native H2A histone or native DNA. A band shift assay further substantiated the enhanced recognition of peroxynitirite-modified H2A histone by anti-DNA autoantibodies. The results suggest that peroxynitrite modification of self-antigen(s) can generate neoepitopes capable of inducing SLE characteristic autoantibodies. The preferential binding of peroxynitrite-modified H2A histone by SLE anti-DNA antibodies points out the likely role of oxidatively modified and nitrated H2A histone in the initiation/progression of SLE. Moreover, oxidatively modified and nitrated nuclear protein antigen, rather than nucleic acid antigens, appear to be more suitable as a trigger for SLE.
Copyright © 2011 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21182886     DOI: 10.1016/j.humimm.2010.12.004

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  6 in total

Review 1.  Spotlights on immunological effects of reactive nitrogen species: When inflammation says nitric oxide.

Authors:  Andrea Predonzani; Bianca Calì; Andrielly Hr Agnellini; Barbara Molon
Journal:  World J Exp Med       Date:  2015-05-20

2.  Systemic lupus erythematosus diagnostics in the 'omics' era.

Authors:  Cristina Arriens; Chandra Mohan
Journal:  Int J Clin Rheumtol       Date:  2013-12-01

Review 3.  Role of peroxynitrite-modified biomolecules in the etiopathogenesis of systemic lupus erythematosus.

Authors:  Rizwan Ahmad; Haseeb Ahsan
Journal:  Clin Exp Med       Date:  2012-11-23       Impact factor: 3.984

4.  Binding of circulating autoantibodies in breast cancer to native and peroxynitrite-modified RNA.

Authors:  Sheereen Tarannum; Zarina Arif; Khursheed Alam
Journal:  J Zhejiang Univ Sci B       Date:  2013-01       Impact factor: 3.066

5.  Dicarbonyl Induced Structural Perturbations Make Histone H1 Highly Immunogenic and Generate an Auto-Immune Response in Cancer.

Authors:  Abdul Rouf Mir; Moin Uddin; Farzana Khan; Khursheed Alam; Asif Ali
Journal:  PLoS One       Date:  2015-08-28       Impact factor: 3.240

6.  Autoantibodies against Modified Histone Peptides in SLE Patients Are Associated with Disease Activity and Lupus Nephritis.

Authors:  Jürgen Dieker; Jo H Berden; Marinka Bakker; Jean-Paul Briand; Sylviane Muller; Reinhard Voll; Christopher Sjöwall; Martin Herrmann; Luuk B Hilbrands; Johan van der Vlag
Journal:  PLoS One       Date:  2016-10-25       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.